Question: after implementing FDA 21 CFR Section 11 rule by the company for not identifying the black spots in the API of the final product intially

after implementing FDA 21 CFR Section 11 rule by the company for not identifying the black spots in the API of the final product intially so what will be the next implemented for patients,the clinical trail individuals and also next for New drug application ?

Step by Step Solution

There are 3 Steps involved in it

1 Expert Approved Answer
Step: 1 Unlock blur-text-image
Question Has Been Solved by an Expert!

Get step-by-step solutions from verified subject matter experts

Step: 2 Unlock
Step: 3 Unlock

Students Have Also Explored These Related General Management Questions!